NEW YORK--(BUSINESS WIRE)--Tyme Technologies Inc. (OTC QB: TYMI), a research and development company focused on developing drug candidates for the treatment of cancer, has announced the appointment of Daniel Petrylak, MD of Yale Oncology as a member of its Medical Advisory Board. Based out of New York, Dr. Petrylak will oversee the Company’s clinical studies. Dr. Petrylak is a pioneer in the research and development of new drugs and treatments to fight prostate, bladder, kidney and testicular cancers. He is currently Professor of Medicine, Director of Genitourinary Oncology and Co-Director of the Signal Transduction Research Program at Yale University.
“It is an honor to have Dr. Petrylak join the Tyme team as a member of our medical advisory board,” said Steve Hoffman, President and CEO of Tyme Technologies Inc. “His knowledge and extensive clinical research background will have a tremendous impact on our ability to advance our clinical program and develop a new drug in the fight against cancer."
Prior to Yale, Dr. Petrylak served as Professor of Medicine at Columbia University Medical Center. He graduated from Columbia College in New York and earned his medical degree from Case Western Reserve University of Medicine in Cleveland, Ohio. He completed his internship and residency in internal medicine at Albert Einstein College of Medicine and went on to complete a fellowship in medical oncology at Memorial Sloan Kettering Cancer Center.
Dr. Petrylak has received several grants and funding support from the National Institutes of Health, private institutions such as CaP CURE and the pharmaceutical industry to study cancer treatments. Since 1995, Dr. Petrylak has been a chairman of the Advanced Bladder Subcommittee of the Southwest Oncology Group, a network of institutions and investigators working to improve the survival of cancer patients through clinical research. He has authored or co-authored more than 100 articles and abstracts in peer-reviewed journals as Cancer, Cancer Research, Clinical Cancer Research, Journal of Clinical Oncology, Journal of the National Cancer Institute, Journal of Urology, Nature and New England Journal of Medicine. Dr. Petrylak has also presented his research at numerous medical conferences, including the American Society of Clinical Oncology and American Urological Association. He has authored several book chapters, reviews and editorials about the treatment of cancers of the prostate, bladder and kidney.
Dr. Petrylak is a member of several medical societies, including the American Association for Cancer Research, the American Society of Clinical Oncology and the American Urological Association. He has also served as a member of the U.S. Food and Drug Administration Immunology Devices Advisory Committee.
About Tyme
Tyme is a pharmaceutical company focused on discovering and developing highly targeted cancer therapeutics for a broad range of oncology indications. Tyme is the originator of what it believes to be a novel, proprietary treatment regimen consisting of a rationally-designed combination of therapeutic agents aimed at exploiting the aberrant metabolic characteristics of cancer cells as well as activating the endogenous immune response against tumors. Tyme's approach is hypothesized to permit selective elimination of cancer cells, while simultaneously improving patients' well-being, particularly with respect to pain severity and functional independence.
Tyme is currently developing for use in humans SM-88, a proprietary compound, which the company believes to be a first-in-class drug that harnesses the body’s own immune defenses to fight tumor cells. SM-88 is a novel combination drug that synergistically targets the unique metabolic features of cancer cells, thus providing a selective method of altering the susceptibility of cancer cells to oxidative stress. Tyme has completed a proof-of-concept clinical study for SM-88 in late-stage cancer patients with relapsed or highly refractory disease and is working towards submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), with the goal of beginning a randomized clinical trial in multiple U.S. centers in the near future. Tyme anticipates an IND submission to the FDA in the second half of 2015.
For more information, visit our website: www.tymetechnologiesinc.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any historical results and future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the factors described in the section captioned "Risk Factors" of Tyme's Current Report on Form 8-K/A filed with the U.S. Securities and Exchange Commission on April 16, 2015 (available at www.sec.gov).
Readers can identify forward-looking statements by terms such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "would" and similar expressions intended to identify forward-looking statements, and forward-looking statements within this press release include statements regarding our drug development strategies, clinical trials and plans for submitting an IND with the FDA. Forward-looking statements reflect the Company’s current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, readers should not place undue reliance on these forward-looking statements.